SCHEMBL25340105

SCHEMBL25340105

Fc1cccc(Br)c1-c1ccc(Cl)cc1S

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GRM2 Q14416 3/20 0.34
▸ PDE2A O00408 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ PTGES O14684 5/20 0.34
▸ KCNH2 Q12809 1/20 0.33
▸ HSD11B1 P28845 2/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ EGLN2 Q96KS0 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20982342 0.82 CXCR2 (0.40) NPC1RAB9AHPGDSMN1; SMN2GRM2
SCHEMBL19802353 0.77 EPHX2 (0.41) NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL19802986 0.77 KMT2A (0.39) PDE2APDE10APTGESCYP1A2CYP3A4
SCHEMBL29534146 0.77 CRHR1 (0.36) NPC1RAB9AHPGDSMN1; SMN2GRM2
SCHEMBL19802354 0.74 KMT2A (0.42) NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL25945211 0.74 GRM2 (0.40) NPC1RAB9AHPGDSMN1; SMN2GRM2
SCHEMBL3570521 0.73 CHRM1 (0.40) NPC1RAB9ASMN1; SMN2PDE2APDE10A
SCHEMBL22129740 0.71 CA1 (0.37) PTGES
SCHEMBL22590245 0.71 ALDH1A1 (0.41) HPGDSMN1; SMN2KCNH2CYP3A4CHRM1
SCHEMBL27253124 0.70 PDK2 (0.41) NPC1RAB9AHPGDSMN1; SMN2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230380283-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE LT MATERIALS CO.,LTD. (KR) 2023-11-23 — — US disclosed
EP-4227303-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE LT Materials Co., Ltd. (KR) 2023-08-16 — — EP disclosed
WO-2022075566-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE 엘티소재주식회사 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230380283-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT-EMITTING DEVICE CYP1B1, CYP4F11, NOTUM NPC1 1877/4885RAB9A 3898/4885HPGD 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback